TELA Bio, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| TELA Bio, Inc. | TELA - NASDAQ |
$14.00-$16.00 | $13.00 | $13.75 | 4 million | 11/8/2019 |
| Jefferies, Piper Jaffray, Canaccord Genuity | ||||||
Co-Manager(s): JMP Securities | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-10-15 Terms Added 2019-10-29 | ||||||
TELA Bio, Inc. Quote & Chart - Click for current quote - TELA
IPO Boutique aggregates information on public companies and private companies, such as "TELA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About TELA Bio, Inc. (adapted from TELA Bio, Inc. prospectus):
They are a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "TELA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.